IN OFFICE DIAGNOSTICS
ONLY 10 MINUTES FROM SPECIMEN TO RESULT!

CRYSTAL DIAGNOSTICS’ XPRESS PATHOGEN DETECTION SYSTEM (CDx)

Liquid Crystal Biosensors, the heart of the CDx rapid pathogen detection system, is the first new medical testing platform for direct patient care in the last 30 years.

FASTER
UNPARALLELED ACCURACY
ECONOMICAL
EASY TO USE

INTRODUCING CDx, THE WORLD’S ONLY DESKTOP LIQUID CRYSTAL BIOSENSOR FOR DISEASE DETECTION - INCLUDING EBOLA ZAIERE!!!

CDx AOAC accredited platform for specific FDA applications, can now be utilized for in-office diagnostics and research. In conjunction with Northeast Ohio Medical University (NEOMED), the CDx platform opens up an entirely new approach to in-office patient care.
PRESS RELEASE

CRYSTAL DIAGNOSTICS SUCCESSFULLY DETECTS DEADLY EBOLA VIRUS IN LESS THAN 20 MINUTES.

JULY 8, 2015; BOULDER, CO/ROOTSTOWN, OH

RAPID EBOLA DETECTION INDICATES THAT THE CDx PLATFORM TECHNOLOGY IS WELL SUITED FOR MEDICAL DEVICE APPLICATIONS.

Crystal Diagnostics (CDx) has successfully detected live Ebola virus with its unique liquid crystal based rapid pathogen detection system. Those tests were conducted at the University of Texas Galveston Medical Branch Biosafety Level 4 (BSL-4) facilities. Tests demonstrated detection at variable concentrations of live Ebola Zaire in serum samples in less than 20 minutes.

The CDx Xpress System combines proprietary liquid crystal technology with highly specific antibody-coated paramagnetic microspheres to selectively capture and detect Ebola virus, faster than other commercial systems. CDx sells rapid pathogen systems in the Food Safety market to quickly and accurately detect food borne pathogens in a variety of products including meat and produce. The Company’s systems are in use in commercial test labs, government agencies, universities, and research facilities, as well as food processors. The Ebola detection project is the first application outside of the food safety arena for CDx.

According to Robert F Garry, PhD, Professor of Microbiology and Immunology at the Tulane University School of Medicine, and Principal Investigator of the Viral Hemorrhagic Fever Consortium (VHFC), "The CDx system promises advantages over other rapid Ebola detection systems, in terms of automated reader results, speed, and consistency."

President and CEO of Crystal Diagnostics, Jim Bruce, stated that, "We are delighted with the initial results, and following field trials and US Food and Drug Administration device approval, we look forward to contributing to the fight against this deadly disease."

CDx has applied for grants from the Paul Allen Foundation and the Biomedical Advanced Research and Development Authority (BARDA), division in the U.S. Department of Health and Human Services, to complete equipment automation and development of the Ebola test.

Critical reagents used in the CDx test were supplied by the Viral Hemorrhagic Fever Consortium, or “VHFC” (www.vhfc.org). The VHFC reagents were developed with the support of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (“NIH/NIAID”). VHFC members Autoimmune Technologies LLC and Zalgen Labs LLC manufacture the critical reagents.

For more information contact Jim Bruce, CEO at 720-351-4885 or visit the CDx web site: www.crystaldiagnostics.com